News stories about ChemoCentryx (NASDAQ:CCXI) have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ChemoCentryx earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 44.7006926826519 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Several equities research analysts recently issued reports on CCXI shares. ValuEngine downgraded ChemoCentryx from a “hold” rating to a “sell” rating in a report on Saturday, October 21st. Zacks Investment Research downgraded ChemoCentryx from a “buy” rating to a “hold” rating in a report on Monday, November 13th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $8.25.
Shares of ChemoCentryx (CCXI) opened at $8.38 on Friday. The stock has a market capitalization of $438.90, a price-to-earnings ratio of -13.97 and a beta of 1.52. ChemoCentryx has a 1-year low of $5.42 and a 1-year high of $10.80.
ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.13. analysts expect that ChemoCentryx will post -0.67 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “ChemoCentryx (CCXI) Earning Somewhat Favorable Media Coverage, Report Finds” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://ledgergazette.com/2018/01/13/chemocentryx-ccxi-earning-somewhat-favorable-media-coverage-report-finds.html.
ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.
Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.